SCHEMBL6029258

SCHEMBL6029258

CCCCCCCCN(CCCCCCCC)C(=O)Nc1sc(C(=O)OCc2ccccc2)c(C)c1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.47
POLB P06746 2/20 0.47
BRAF P15056 1/20 0.41
TSHR P16473 3/20 0.41
RAB9A P51151 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
CCKBR P32239 1/20 0.40
ALDH1A1 P00352 8/20 0.40
HPGD P15428 2/20 0.40
KDM4E B2RXH2 2/20 0.40
LMNA P02545 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPK1 P28482 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NPSR1 Q6W5P4 2/20 0.40
APOBEC3G Q9HC16 1/20 0.39
PKM P14618 1/20 0.39
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6030298 0.91 MAPT (0.46) MAPTPOLBBRAFTSHRRAB9A
SCHEMBL6030484 0.84 MAPT (0.48) MAPTPOLBBRAFTSHRRAB9A
SCHEMBL6029449 0.83 MAPT (0.52) MAPTPOLBTSHRALDH1A1HPGD
SCHEMBL6029726 0.82 MAPT (0.48) MAPTPOLBBRAFTSHRRAB9A
SCHEMBL6029529 0.82 MAPT (0.43) MAPTPOLBBRAFTSHRRAB9A
SCHEMBL6031228 0.80 MAPT (0.47) MAPTPOLBBRAFTSHRRAB9A
SCHEMBL3490918 0.80 ALDH1A1 (0.59) MAPTPOLBBRAFTSHRRAB9A
SCHEMBL8042616 0.78 ALDH1A1 (0.59) MAPTPOLBBRAFTSHRRAB9A
SCHEMBL8058314 0.77 ALDH1A1 (0.55) MAPTPOLBBRAFTSHRRAB9A
SCHEMBL6029728 0.77 ALDH1A1 (0.47) MAPTPOLBSMN1; SMN2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064122-B2 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2006-06-20 US disclosed
EP-1467978-A4 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARM INC (US) 2005-11-02 EP disclosed
EP-1467978-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI Pharmaceuticals, Inc. (US) 2004-10-20 EP disclosed
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-10-16 US disclosed
WO-2003053944-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARMACEUTICALS, INC. (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use PNLIP, LIPC, CEL MAPT 4105/4885POLB 2788/4885BRAF 4234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.